Bridging Language and Medicine: Best Practices in French Regulatory Medical Writing with a Focus on Terminology

Summary

This article goes beyond theoretical recommendations, examining recurring linguistic and terminological issues or challenges and providing practical insights in French normative regulatory medical documents, particularly in English-to-French contexts, with a focus on linguistic risk management. Rather than focusing on isolated translation errors, it highlights decision points where terminology and linguistic choices intersect with regulatory usage, clinical practice and documentation consistency. It also provides concrete and context-appropriate alternatives that help bridge the gap between official recommendations and real-world practice.
The aim of this article is to support more informed terminology management in regulatory medical translation and writing by identifying overlooked linguistic risks and emphasizing the importance of context-driven and regulatory-aware decision-making.

Introduction

This article is intended for professionals working in medical translation and regulatory writing, particularly related to human medicinal products. It focuses on regulated medical documentation aimed at healthcare professionals, referred to here as normative regulatory medical documents, as opposed to regulated medical content for lay audiences (which will be addressed in a separate article).
While normative regulatory documentation encompasses a wide range of materials, particular emphasis is placed on the Summary of Product Characteristics (SmPC or "RCP" in French) in this article. Some others, such as Investigator Brochures (IB) and clinical trial protocols, are referenced where relevant.

Although IB and protocols are intended for prescribers and clinical investigators, their use and circulation remain largely confined to the clinical trial setting. The SmPC, by contrast, is broadly disseminated to all healthcare professionals. As a result, while all these documents require a high level of precision and conceptual equivalence in translation, the SmPC represents the highest level of linguistic and regulatory sensitivity: any terminological imprecision or interpretative inaccuracy may have direct regulatory and safety consequences, outside the controlled environment of a clinical trial.
It is often assumed that ensuring compliance with regulatory requirements (e.g. adherence to QRD templates, MedDRA coding and EDQM terminology) is sufficient to produce a correct target-language document, but this is the regulatory equivalent of believing that following a cake recipe guarantees a perfect dessert. This is technically true but dangerously optimistic. Compliance is compulsory, but it does not automatically guarantee clarity or immediate comprehension by the target audience.
When working as a medical linguist, I have often encountered sentences in French regulatory documents that I cannot fully understand until reading the corresponding sentence in the English version. Remaining too close to English phrasing not only produces non-idiomatic French but also decreases clinical readability, which can have important implications for safety, submitted regulatory dossiers and even financial outcomes.
This article therefore focuses on the management of medical terminology in close alignment with regulatory requirements. It demonstrates that a linguistically informed approach, balancing regulatory compliance, idiomatic French usage and recognized linguistic standards, significantly improves both the clarity and credibility of regulatory documents. It also provides concrete and balanced alternatives to common pitfalls in French medical translation.
It is worth noting that the terminological guidance in this article applies particularly to French as used in France, which broadly aligns with conventions followed by other French-speaking regulatory contexts (e.g. North African countries). Terminology localization remains crucial in medical translation and writing, as terms used in Canadian French, for example, can create confusion for other French healthcare professionals (e.g. "forme posologique" versus "forme pharmaceutique", or "cuillère à thé" versus "cuillère à café"). Additionally, many anglicisms are widely accepted or even recommended in Canadian French, but in French for France they may be perceived as unusual and/or incorrect.

A practical tip for all translators and medical writers: read the produced text as if you were a healthcare professional under time pressure. If a sentence makes you pause, it will make its readers pause too. Regulatory documents must not only be compliant but also immediately comprehensible and clinically safe for their target audience.

Bridging Language and Medicine: Best Practices in French Regulatory Medical Writing with a Focus on Terminology

Summary

Introduction

Table of Contents